Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
PH-ACP3GA-01/24
Philogen S.p.A.
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-ACP3GA-03/25
Philogen S.p.A.
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
PH-CAIXGA-02/24
Philogen S.p.A.
Patients with suspected clear cell renal cell carcinoma (ccRCC)
1 trial -
PH-FAPLU-02-23
Philogen S.p.A.
Patients with advanced/metastatic FAP-positive tumors
1 trial -
PH-L19IL2CORK-01/25
Philogen S.p.A.
Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
1 trial -
PIC1 Injection
Chongqing Precision Biotech Co., Ltd
Non-Hodgkin Lymphoma
1 trial -
PIVEKIMAB SUNIRINE
AbbVie Deutschland GmbH & Co. KG
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
1 trial -
PLATFORMPACAN1001
Janssen-Cilag International N.V.
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
1 trial -
PLN-101095
PLIANT THERAPEUTICS, INC.
Advanced or Metastatic Solid Tumor
1 trial -
PM14-A-003-20
Lacuna Pharma Pty Ltd
Advanced solid tumors
1 trial -
PONAT-14-25
Lacuna Pharma Pty Ltd
chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia
1 trial -
PRG2302
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
PRIMROSE D9970C00001
AstraZeneca AB
Advanced/metastatic solid tumors that are MTAP deficient.
1 trial -
PRT1419
Prelude Therapeutics Inc
Sarcoma
1 trial -
PRT1419
Prelude Therapeutics Inc
Acute Myeloid Leukemia
1 trial -
PRT2527
Prelude Therapeutics Inc
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
1 trial -
PRT2527
Prelude Therapeutics Inc
Sarcoma
1 trial -
PRT3645
Prelude Therapeutics Inc
Breast Cancer
1 trial -
PRT543
Prelude Therapeutics Inc
Relapsed/Refractory Advanced Solid Tumors
1 trial -
PRT7732
Prelude Therapeutics Inc
Advanced Solid Tumor
1 trial -
PRT7732-01
Prelude Therapeutics Inc
esophageal, gastric, or gastroesophageal junction adenocarcinoma, esophageal, gastric, or gastroesophageal junction squamous cell carcinoma, Non-small cell lung cancer (NSCLC), Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
1 trial -
PRT811
Prelude Therapeutics Inc
Advanced Solid Tumor
1 trial -
PSA/IL-2/GM-CSF
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
PTC299
PTC THERAPEUTICS, INC.
Advanced Cancer
1 trial -
PTC299
PTC THERAPEUTICS, INC.
Leukemia, Myeloid, Acute
1 trial -
PTC299
PTC THERAPEUTICS, INC.
Metastatic Breast Cancer
1 trial -
PTC596
PTC THERAPEUTICS, INC.
Cancer
1 trial -
PV-10 (10% rose bengal disodium)
PROVECTUS BIOPHARMACEUTICALS, INC.
Cancer Metastatic to the Liver
1 trial -
PV-10 (rose bengal disodium 10%)
PROVECTUS BIOPHARMACEUTICALS, INC.
Breast Cancer
1 trial -
PV-10 (rose bengal disodium, 10%)
PROVECTUS BIOPHARMACEUTICALS, INC.
Melanoma
1 trial -
PVSRIPO
United Therapeutics Europe Ltd
Invasive Breast Cancer
1 trial -
PYX-106
Pyxis Oncology
Solid Tumor
1 trial -
PYX-201
Pyxis Oncology
Solid Tumor
1 trial -
Paclitaxel
Jazz Pharmaceuticals Ireland Limited
Ovarian Cancer
1 trial -
Paclitaxel
Hospital Authority, Hong Kong
Ovarian Cancer
1 trial -
Palazestrant
Olema Pharmaceuticals
Metastatic Breast Cancer
1 trial -
Part 1 TPST-1120
Tempest Therapeutics
Hepatocellular Carcinoma
1 trial -
Part A: Dose Escalation of Cantrixil
KAZIA THERAPEUTICS LTD
Ovarian Neoplasms
1 trial -
Pazopanib
GlaxoSmithKline
Neoplasms, Colorectal
1 trial -
Pegfilgrastim
Biotech Pharmaceutical Co.,
Breast Cancer
1 trial -
Pelareorep
ONCOLYTICS BIOTECH INC
Breast Cancer
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Cervix Cancer
1 trial -
Pembrolizumab
Cardiff Oncology
Anal Cancer Stage III A
1 trial -
Pembrolizumab
Takeda
Carcinoma, Non-Small-Cell Lung
1 trial -
Pevonedistat
Takeda
Advanced Solid Tumors, Neoplasms, Advanced Solid
1 trial -
Pevonedistat
Takeda
Advanced Solid Neoplasm
2 trials -
Pevonedistat
Takeda
Acute Myelogenous Leukemia
1 trial -
Pevonedistat
Takeda
Refractory Acute Lymphoblastic Leukemia
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.